Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Korean Med Sci. 2013 Aug;28(8):1248-52. doi: 10.3346/jkms.2013.28.8.1248. Epub 2013 Jul 31.
Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib dosage by plasma level monitoring may facilitate management of patients who experience intolerable toxicities due to overexposure to the drug. We present two cases of advanced GIST patients in whom we managed imatinib-related toxicities through dose modifications guided by imatinib plasma level monitoring. Imatinib blood level testing may be a promising approach for fine-tuning imatinib dosage for better tolerability and optimal clinical outcomes in patients with advanced GIST.
伊马替尼是晚期胃肠道间质瘤（GIST）患者的一线治疗药物，一般耐受性良好，尽管有些患者难以耐受标准剂量的 400mg/天。通过监测血浆水平调整伊马替尼剂量可能有助于管理因药物暴露过度而出现无法耐受毒性的患者。我们报告了两例晚期 GIST 患者的病例，我们通过伊马替尼血浆水平监测指导的剂量调整来管理与伊马替尼相关的毒性。伊马替尼血药浓度检测可能是一种有前途的方法，可以调整伊马替尼剂量，以提高晚期 GIST 患者的耐受性和获得最佳的临床结果。
